Entellus Medical to Report Third Quarter 2015 Financial Results on November 5, 2015
23 October 2015 - 7:02AM
Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company
focused on delivering superior patient and physician experiences
through products designed for the minimally invasive treatment of
chronic and recurrent sinusitis patients, today announced that it
will release its financial results for the third quarter of 2015
after the close of trading on Thursday, November 5, 2015. The
Company's management team will host a corresponding conference call
beginning at 3:30pm CT/4:30pm ET to discuss the financial results
and recent business developments.
Individuals interested in listening to the conference call may
do so by dialing (877) 930-5751 for domestic callers or (253)
336-7277 for international callers, using Conference ID: 50165626.
To listen to a live webcast, please visit the investor relations
section of the Entellus Medical website at:
www.entellusmedical.com.
A replay of the call will be available beginning November 5,
2015 at 6:30pm CT/7:30pm ET through midnight ET on November 6,
2015. To access the replay, dial (855) 859-2056 or (404) 537-3406
and reference Conference ID: 50165626. The webcast will also be
available on the Entellus Medical website for one month following
the completion of the call.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on
delivering superior patient and physician experiences through
products designed for the minimally invasive treatment of chronic
and recurrent sinusitis patients. The Entellus Medical platform of
products provides physicians with solutions to aid in the diagnosis
and treatment of patients suffering from chronic
sinusitis. Its XprESS family of products is used by ENT
physicians to open narrowed or obstructed sinus drainage pathways
using balloon sinus dilation. When used as a stand-alone therapy,
Entellus Medical's balloon sinus dilation products are the only
devices proven in a sufficiently powered prospective, multicenter,
randomized, controlled trial to be as effective as functional
endoscopic sinus surgery ("FESS"). Patients treated with Entellus
Medical's products in this trial in the ENT physician's office also
experienced faster recovery, less bleeding at discharge, less use
of prescription pain medication and fewer post-procedure
debridements than patients receiving FESS. In addition to its
XprESS line of products, Entellus Medical has recently introduced
additional products designed to aid in the diagnosis, treatment and
post-operative care of patients suffering from chronic
sinusitis.
Entellus Medical currently markets its products in the United
States, Europe and Canada and sells its products through a direct
sales force in the United States and the United Kingdom. For more
information, please visit the Company's website at
www.entellusmedical.com.
CONTACT: Leigh Salvo
415-513-1281
ir@entellusmedical.com
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Entellus Medical, Inc. (delisted) (NASDAQ): 0 recent articles
More News Articles